Warning! GuruFocus detected
2 Medium warning signs
with 8AK.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Alkermes PLC
NAICS : 325412
SIC : 2834
ISIN : IE00B56GVS15
Description
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.95 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 0.15 | |||||
| Interest Coverage | 18.63 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 6.36 | |||||
| Beneish M-Score | -2.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.9 | |||||
| 3-Year EBITDA Growth Rate | 39.5 | |||||
| 3-Year EPS without NRI Growth Rate | 84.1 | |||||
| 3-Year FCF Growth Rate | 75.8 | |||||
| 3-Year Book Growth Rate | 9.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -16.03 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 4.48 | |||||
| 9-Day RSI | 12.97 | |||||
| 14-Day RSI | 21.6 | |||||
| 3-1 Month Momentum % | 17.04 | |||||
| 6-1 Month Momentum % | 21.54 | |||||
| 12-1 Month Momentum % | 33.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.04 | |||||
| Quick Ratio | 2.65 | |||||
| Cash Ratio | 1.62 | |||||
| Days Inventory | 283.71 | |||||
| Days Sales Outstanding | 74.72 | |||||
| Days Payable | 98.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 5.95 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.25 | |||||
| Operating Margin % | 27.01 | |||||
| Net Margin % | 23.57 | |||||
| FCF Margin % | 26.26 | |||||
| ROE % | 28.24 | |||||
| ROA % | 17.19 | |||||
| ROIC % | 38.55 | |||||
| 3-Year ROIIC % | -132.06 | |||||
| ROC (Joel Greenblatt) % | 95.94 | |||||
| ROCE % | 28.21 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.14 | |||||
| Forward PE Ratio | 15.69 | |||||
| PE Ratio without NRI | 11.18 | |||||
| Price-to-Owner-Earnings | 16.65 | |||||
| PS Ratio | 3.09 | |||||
| PB Ratio | 3.16 | |||||
| Price-to-Tangible-Book | 3.35 | |||||
| Price-to-Free-Cash-Flow | 11.82 | |||||
| Price-to-Operating-Cash-Flow | 10.93 | |||||
| EV-to-EBIT | 8.88 | |||||
| EV-to-Forward-EBIT | 13.98 | |||||
| EV-to-EBITDA | 8.37 | |||||
| EV-to-Forward-EBITDA | 12.79 | |||||
| EV-to-Revenue | 2.66 | |||||
| EV-to-Forward-Revenue | 2.95 | |||||
| EV-to-FCF | 10.38 | |||||
| Price-to-GF-Value | 0.92 | |||||
| Price-to-Projected-FCF | 1.85 | |||||
| Price-to-Median-PS-Value | 0.81 | |||||
| Price-to-Graham-Number | 1.29 | |||||
| Price-to-Net-Current-Asset-Value | 5.6 | |||||
| Price-to-Net-Cash | 28.79 | |||||
| Earnings Yield (Greenblatt) % | 11.25 | |||||
| FCF Yield % | 8.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alkermes PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,444.479 | ||
| EPS (TTM) (€) | 2.021 | ||
| Beta | 0.35 | ||
| 3-Year Sharpe Ratio | 0.42 | ||
| 3-Year Sortino Ratio | 0.68 | ||
| Volatility % | 28.95 | ||
| 14-Day RSI | 21.6 | ||
| 14-Day ATR (€) | 0.571903 | ||
| 20-Day SMA (€) | 30.45 | ||
| 12-1 Month Momentum % | 33.9 | ||
| 52-Week Range (€) | 20.8 - 34.6 | ||
| Shares Outstanding (Mil) | 162.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alkermes PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alkermes PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alkermes PLC Frequently Asked Questions
What is Alkermes PLC(FRA:8AK)'s stock price today?
The current price of FRA:8AK is €26.20. The 52 week high of FRA:8AK is €34.60 and 52 week low is €20.80.
When is next earnings date of Alkermes PLC(FRA:8AK)?
The next earnings date of Alkermes PLC(FRA:8AK) is 2025-05-01 Est..
Does Alkermes PLC(FRA:8AK) pay dividends? If so, how much?
Alkermes PLC(FRA:8AK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers